Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis forU.S./Canada Rights to Novel Epinephrine Auto-injector

By Pharmaceutical Processing | November 30, 2009

Intelliject, Inc. today announcedan exclusive license with sanofi-aventis U.S. for a novel epinephrineauto-injector, in the U.S. and Canada territory. Under the license,sanofi-aventis U.S. shall be responsible for manufacturing andcommercialization. Intelliject will be responsible for the on-goingdevelopment and for obtaining U.S. regulatory approval and has retainedcertain co-promotion rights in the territory. Sanofi-aventis U.S. will pay an initial upfront payment of $25 million.Intelliject will also be eligible to receive development and commercialmilestones of up to $205 million as well as tiered double-digit royalties onsales of any products commercialized under the license. “We are delighted to have sanofi-aventis U.S. as our partner with theirproven track record in and commitment to the allergy/immunology area. Thispartnership marks a key milestone in our quest to make our novel epinephrineauto-injector available to the millions of patients at risk for anaphylaxis.We expect it to create significant long-term value for the company; it marksthe first step on our mission to bring the same innovation and patient-centricsolutions to many different therapy areas. Intelliject’s unique model — drugdevelopment expertise combined with a proprietary, patient-centric deliveryplatform — has the potential to dramatically redefine the “Standard of Care”in multiple biopharmaceutical categories,” said Spencer Williamson, Presidentand CEO of Intelliject.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards